CoChat

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

Open access
Yan, Wen-Ting, Cui, Xiang, Chen, Qing, Li, Ya-Fei, Cui, You-Hong, Wang, Yan, Jiang, Jun · 2017 · Scientific Reports

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Abstract

Whether circulating tumor cells (CTCs) can be used as an indicator of treatment response in breast cancer (BC) needs to be clarified. We addressed this issue by a meta-analysis. PubMed, EMBase and Cochrane library databases were searched in June 2016. Effect measures were estimated as pooled risk ratio (RR), odds ratio (OR) or mean difference by fixed- or random-effect models, according to heterogeneity of included studies. In total, 50 studies with 6712 patients were recruited. Overall analysis showed that there was a significant reduction of CTC-positive rate (RR = 0.68, 95% CI: 0.61–0.76, P < 0.00001) after treatment. Subgroup analyses revealed that neoadjuvant treatment, adjuvant treatment, metastatic treatment or combination therapy could reduce the CTC-positive rate, but surgery could not; moreover, the reduction was only found in HER2+ or HER2- patients but not in the triple-negative ones. Reduction of CTC-positive rate was associated with lower probability of disease progression (OR = 0.54, 95% CI: 0.33–0.89, P = 0.01) and longer overall survival period (mean difference = 11.61 months, 95% CI: 8.63–14.59, P < 0.00001) as well as longer progression-free survival period (mean difference = 5.07 months, 95% CI: 2.70–7.44, P < 0.0001). These results demonstrate that CTC status can serve as an indicator to monitor the effectiveness of treatments and guide subsequent therapies in BC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep43464

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flowchart for article search.
Figure 1 Flowchart for article search.CC BY · PubMed Central
Figure 2 Forest plot for the comparison of CTC-positive rate before and after treatment: overall analysis. The black diamond and its extremities indicate the pooled risk ratio center and 95% confidential interval.
Figure 2 Forest plot for the comparison of CTC-positive rate before and after treatment: overall analysis. The black diamond and its extremities indicate the pooled risk ratio center and 95% confidential interval.CC BY · PubMed Central
Figure 3 Forest plot for the comparison of CTC count before and after treatment: overall analysis. The black diamond indicates the difference of CTC counts (cells/7.5 mL peripheral blood; the post-therapeutic counts minus the pre-therapeutic counts). Its center indicates the mean and the extremities indicate the 95% confidential interval.
Figure 3 Forest plot for the comparison of CTC count before and after treatment: overall analysis. The black diamond indicates the difference of CTC counts (cells/7.5 mL peripheral blood; the post-therapeutic counts minus the pre-therapeutic counts). Its center indicates the mean and the extremities indicate the 95% confidential interval.CC BY · PubMed Central
Figure 4 Forest plot for the comparison of CTC-positive rate before and after treatment: subgroup analysis of different CTC determination methods (threshold). The results of ≥5 CTCs/7.5 mL as positive (A) ≥1 CTCs/7.5 mL as positive (B) other threshold as positive (C) and RT-PCR method (D) are shown, respectively. The center of black diamond and its extremities indicate the pooled risk ratio and 95% confidential interval.
Figure 4 Forest plot for the comparison of CTC-positive rate before and after treatment: subgroup analysis of different CTC determination methods (threshold). The results of ≥5 CTCs/7.5 mL as positive (A) ≥1 CTCs/7.5 mL as positive (B) other threshold as positive (C) and RT-PCR method (D) are shown, respectively. The center of black diamond and its extremities indicate the pooled risk ratio and 95% confidential interval.CC BY · PubMed Central
Figure 5 Forest plot for the comparison of CTC-positive rate before and after treatment: subgroup analysis of different therapy strategies. The results of neoadjuvant setting (A), adjuvant setting (B), metastatic setting (C), surgery (D) and combination therapy (E) are shown, respectively. The center of black diamond and its extremities indicate the pooled risk ratio and 95% confidential interval.
Figure 5 Forest plot for the comparison of CTC-positive rate before and after treatment: subgroup analysis of different therapy strategies. The results of neoadjuvant setting (A), adjuvant setting (B), metastatic setting (C), surgery (D) and combination therapy (E) are shown, respectively. The center of black diamond and its extremities indicate the pooled risk ratio and 95% confidential interval.CC BY · PubMed Central
Figure 6 Forest plot for the comparison of CTC-positive rate before and after treatment: subgroup analysis of different molecular subtypes. The results of HER2-positive subtype (A) HER2-negative subtype (B) and triple-negative subtype (C) are shown, respectively. The black diamond and its extremities indicate the pooled risk ratio center and 95% confidential interval.
Figure 6 Forest plot for the comparison of CTC-positive rate before and after treatment: subgroup analysis of different molecular subtypes. The results of HER2-positive subtype (A) HER2-negative subtype (B) and triple-negative subtype (C) are shown, respectively. The black diamond and its extremities indicate the pooled risk ratio center and 95% confidential interval.CC BY · PubMed Central
Figure 7 Forest plot for the comparison of prognosis between the CTC-reduced patients and those without CTC-unchanged or -elevated. The diamond indicated the odds ratio of disease progression (A) the difference of progression-free survival (B) or overall survival period (C). The centers of the diamonds indicated the pooled odds ratio (A) or the mean difference (B,C) and the extremities indicated the 95% confidential interval.
Figure 7 Forest plot for the comparison of prognosis between the CTC-reduced patients and those without CTC-unchanged or -elevated. The diamond indicated the odds ratio of disease progression (A) the difference of progression-free survival (B) or overall survival period (C). The centers of the diamonds indicated the pooled odds ratio (A) or the mean difference (B,C) and the extremities indicated the 95% confidential interval.CC BY · PubMed Central
Figure 8 Forest plot for the comparison of prognosis between the CTC-reduced patients and those without CTC-unchanged or –elevated: subgroup analysis of disease progression. The diamond indicated the odds ratio of disease progression in the metastatic setting (A), the adjuvant setting (B) or the neoadjuvant setting (C). The centers of the diamonds indicated the pooled odds ratio and the extremities indicated the 95% confidential interval.
Figure 8 Forest plot for the comparison of prognosis between the CTC-reduced patients and those without CTC-unchanged or –elevated: subgroup analysis of disease progression. The diamond indicated the odds ratio of disease progression in the metastatic setting (A), the adjuvant setting (B) or the neoadjuvant setting (C). The centers of the diamonds indicated the pooled odds ratio and the extremities indicated the 95% confidential interval.CC BY · PubMed Central
Figure 9 Funnel plot for the studies included for comparison of CTC-positive rate before and after treatment.
Figure 9 Funnel plot for the studies included for comparison of CTC-positive rate before and after treatment.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 114

Metadata

Authors
Yan, W.-T., Cui, X., Chen, Q., Li, Y.-F., Cui, Y.-H., Wang, Y., & Jiang, J.
Affiliations
Army Medical University (CN)
Corresponding author
Jiang, Jun
Venue
Scientific Reports
Published
2017-03-24
Volume
7
Issue
1
Pages
43464-43464
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2599986806
Cited by
113
References
64
Citations by year
2026: 1 · 2025: 3 · 2024: 6 · 2023: 16 · 2022: 14 · 2021: 20 · 2020: 20 · 2019: 19 · 2018: 12 · 2017: 1
FWCI
1.45
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
circulating tumor cells, breast cancer, treatment response monitoring, neoadjuvant therapy, adjuvant therapy, metastatic breast cancer, HER2-positive breast cancer, triple-negative breast cancer, disease progression, overall survival, progression-free survival
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Monitoring, Physiologic, Neoplastic Cells, Circulating, Prognosis, Risk Factors, Biomarkers, Tumor, Gene Expression, Odds Ratio, Survival Analysis, Disease Progression, Erb-b2 Receptor Tyrosine Kinases, Neoadjuvant Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.